LBPO.PR01 · 预防研究 · Late-Breaking
早期巨噬细胞重编程驱动 BRCA1 相关乳腺癌的发生
Early macrophage reprogramming drives BRCA1 associated breast cancer initiation
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
乳腺癌相关基因 1(BRCA1)突变型乳腺癌是一种侵袭性疾病亚型,传统上归因于遗传不稳定性的累积。然而,新兴证据表明,组织微环境中的非遗传因素(包括免疫细胞)在疾病发生中发挥关键作用。虽然许多乳腺肿瘤被认为在免疫学上是「冷」的,但 BRCA1 缺陷型肿瘤表现出更高的免疫细胞浸润,提示存在独特的免疫格局。为界定与 BRCA1 缺失相关的免疫改变,我们利用了一种乳腺特异性敲除 Brca1 和 Trp53 的基因工程小鼠模型,并结合对人类 BRCA1 突变携带者组织的分析。采用单细胞 RNA 测序、空间蛋白质组学、流式细胞术和免疫荧光,我们全面表征了 BRCA1 相关肿瘤发生过程中的免疫重塑。单细胞和流式细胞分析揭示,在癌前阶段,BRCA1 突变型乳腺中促炎巨噬细胞显著扩增。随着疾病进展,这伴随着从组织驻留型到炎症型巨噬细胞状态的表型转变。空间蛋白质组学分析表明,在肿瘤形成之前,免疫细胞已在突变组织中早期蓄积,其中 F4/80⁺ 巨噬细胞优先定位于上皮结构周围。使用乳腺上皮类器官与从 BRCA1 突变型乳腺分离的巨噬细胞共培养的功能实验显示上皮生长和分支增加。细胞间通讯分析将 oncostatin M 确定为该表型的候选介导因子,用重组 oncostatin M 处理足以增强 BRCA1 突变型类器官的生长和分支。值得注意的是,在人类 BRCA1 突变携带者的乳腺组织中观察到类似的促炎巨噬细胞特征。总之,这些发现表明,炎症性巨噬细胞在 BRCA1 缺失后早期出现,并积极促进与肿瘤发生相关的上皮重塑。靶向早期巨噬细胞-上皮相互作用可能代表一种针对高遗传风险个体的新型癌症预防策略,凸显了在 BRCA1 突变携带者中针对巨噬细胞的干预措施的治疗潜力。
查看英文原文 English abstract
Breast cancer associated gene 1 (BRCA1) mutant breast cancer is an aggressive disease subtype traditionally attributed to the accumulation of genetic instability. However, emerging evidence suggests that non genetic factors within the tissue microenvironment, including immune cells, play critical roles in disease initiation. While many breast tumors are considered immunologically cold, BRCA1 deficient tumors display higher immune cell infiltration, indicating a distinct immune landscape. To define immune alterations associated with BRCA1 loss, we utilized a genetically engineered mouse model with mammary specific deletion of Brca1 and Trp53 , complemented by analysis of tissues from human BRCA1 mutation carriers. Using single cell RNA sequencing, spatial proteomics, flow cytometry, and immunofluorescence, we comprehensively characterized immune remodeling during BRCA1 associated tumor initiation. Single-cell and flow cytometric analyses revealed a marked expansion of pro-inflammatory macrophages in BRCA1 mutant mammary glands at the premalignant stage. This was accompanied by a phenotypic shift from tissue-resident to inflammatory macrophage states as disease progressed. Spatial proteomic profiling demonstrated early accumulation of immune cells in mutant tissues prior to tumor formation with F4/80⁺ macrophages preferentially localizing around epithelial structures. Functional assays using mammary epithelial organoids co-cultured with macrophages isolated from BRCA1 mutant glands showed increased epithelial growth and branching. Cell - cell communication analysis identified oncostatin M as a candidate mediator of this phenotype, and treatment with recombinant oncostatin M was sufficient to enhance growth and branching of BRCA1 mutant organoids. Notably, similar pro inflammatory macrophage signatures were observed in breast tissues from human BRCA1 mutation carriers.Together, these findings demonstrate that inflammatory macrophages emerge early following BRCA1 loss and actively promote epithelial remodeling associated with tumor initiation. Targeting early macrophage - epithelial interactions may represent a novel cancer prevention strategy for individuals at high genetic risk, highlighting the therapeutic potential of macrophage directed interventions in BRCA1 mutation carriers.
利益披露 Disclosure
A. Prem Antony Samy, None..
I. Adam, None..
V. Mai, None..
T. Lev, None..
M. Pein, None..
S. Mallya, None..
J. Gonzalez, None..
P. Naef, None..
E. Zagni, None..
J. Berari, None..
E. Zhao, None..
H. Savage, None..
D. Lawson, None.